Results 21 to 30 of about 345,374 (311)

Massive thrombosis and phlegmasia cerulea dolens while taking rivaroxaban: case report and review [PDF]

Jornal Vascular Brasileiro, 2021
Our study describes a fatal case of phlegmasia cerulea dolens and massive venous thrombosis in a patient taking rivaroxaban regularly to treat cerebral venous sinus thrombosis. Blood tests samples were positive for lupus anticoagulant.
Diego Chemello, Larissa Rosa, Amanda Faria de Araujo, Pedro Cargnelutti de Araujo, Luiz Carlos Carneiro Pereira, Suélen Feijó Hillesheim, Marco Aurélio Lumertz Saffi   +6 more
doaj   +1 more source

Lupus anticoagulant. [PDF]

Stroke, 1987
Summary Circulating lupus anticoagulant occurs in 5–37% of all patients with systemic lupus erythematosus. Its occurrence is not restricted to collagen vascular disease states. Lupus anticoagulant causes a prolongation of certain laboratory coagulation studies yet it is associated in vivo with a history of systemic intravascular ...
N A, Aunsholt, J, Stentoft
  +8 more sources

Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

Journal of Thrombosis and Haemostasis, 2022
Diagnosis of antiphospholipid syndrome (APS) requires persistent presence of lupus anticoagulant (LAC), anticardiolipin (aCL) IgG/IgM, or anti‐β2 glycoprotein I (aβ2GPI) IgG/IgM antibodies.
A. Vandevelde, W. Chayoua, B. de Laat, G. Moore, J. Musial, S. Zuily, D. Wahl, K. Devreese   +7 more
semanticscholar   +1 more source

Laboratory Identification of Lupus Anticoagulant (LA) Using Different Activated Partial Thromboplastin Time (APTT) Assays. [PDF]

Int J Lab Hematol
ABSTRACT Introduction The International Society of Thrombosis and Hemostasis (ISTH) guidelines suggest a three‐step evaluation for the detection of lupus anticoagulant (LA), including screening, mixing, and confirmation. According to the guidelines, the LA assay based on activated partial thromboplastin time (APTT) should include an initial screening ...
Barion BG, Stefanello B, de Paula MLSA, Saraiva TS, Villaça PR, Rocha V, Orsi FA, da Rocha TRF.   +7 more
europepmc   +2 more sources

Cancer History, Antiphospholipid Syndrome, and Lupus Anticoagulant: A Perfect Storm for Thrombosis. [PDF]

Cureus
Carpintieri S, Uyar E, Anand C, Buryk Y.
europepmc   +3 more sources

International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

Journal of Thrombosis and Haemostasis, 2021
Lupus anticoagulant (LA) assays are compromised in anticoagulated patients, and existing strategies to overcome the interferences have limitations. The prothrombin‐activating Taipan snake venom time (TSVT) screening test and ecarin time (ET) confirmatory
G. Moore, Paul O. Jones, S. Platton, Nadia Hussain, D. White, W. Thomas, Joseph Rigano, C. Pouplard, E. Gray, K. Devreese   +9 more
semanticscholar   +1 more source

Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature

Seminars in Thrombosis and Hemostasis, 2021
The term “lupus anticoagulant (LA)” identifies a form of antiphospholipid antibodies (aPLs) causing prolongation of clotting tests in a phospholipid concentration-dependent manner.
E. Favaloro, B. Henry, G. Lippi
semanticscholar   +1 more source

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

Research and Practice in Thrombosis and Haemostasis, 2021
The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with antiphospholipid
S. A. Baker, Jing Jin, C. Pfaffroth, T. Vũ, J. Zehnder   +4 more
semanticscholar   +1 more source

Lupus Anticoagulant Is Associated with Critical Cases and High Mortality in COVID-19: A Literature Review. [PDF]

Tanaffos, 2023
Moafi M, Ebrahimi MJ, Hatami F, Javandoust Gharehbagh F, Ahmadzadeh A, Emam MM, Rajaei A, Mansouri D, Alavi Darazam I.   +8 more
europepmc   +2 more sources

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

New England Journal of Medicine, 2020
Prolonged aPTT in Patients with Covid-19 In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time.
L. Bowles, S. Platton, Nada Yartey, Minal Dave, Kurtis Lee, D. Hart, Vickie MacDonald, Laura Green, S. Sivapalaratnam, K. Pasi, P. Maccallum   +10 more
semanticscholar   +1 more source